Research programme: leukaemia therapeutics - Swedish Orphan Biovitrum/Karolinska Development
Latest Information Update: 06 Mar 2012
At a glance
- Originator Biovitrum
- Developer Biovitrum - Karolinska Development (JV)
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Leukaemia